This study aims to evaluate the potential of recombinant human Neuregulin1 beta 1 (rhNRGβ1) to inhibit schwannoma growth and promote Schwann cell differentiation in preclinical models.<h4>Methods</h4>We investigated the therapeutic potential of rhNRGβ1, a recombinant human epidermal growth factor (EGF)-like domain of Neuregulin1 beta 1, as a growth-inhibitory agent for schwannomas. Here, EGF is linked to schwannoma.